OriGene Technologies develops and markets biotechnology products and biological reagents for research laboratories, diagnostic companies, clinics and hospitals. Its product portfolio includes cDNA, proteins and antibodies and it provides technological solutions for in‑vitro diagnostics and immunohistochemistry. The company serves both research and clinical diagnostic markets. OriGene plans to use the recent funding to deepen cooperation with global laboratories and to grow product sales in Europe. Founded in 1996 by Weiwu He, the company is based in Rockville, Maryland. The article does not report operating metrics or detailed financials. OriGene Technologies is a Rockville, MD–based genome wide product company that develops, manufactures and sells research and diagnostic products worldwide. Led by Wei-Wu He, Ph.D., Chairman and Chief Executive Officer, the company has developed an array of ultra-specific monoclonal antibodies called UltraMAB™, validated by its proprietary high-density microarray technology for a wide variety of applications. OriGene markets these products for research and diagnostic use globally. The company completed a $21.3M Series C financing to support its business. It intends to use the proceeds to advance its growth strategy and operations. OriGene Technologies is a Rockville, MD-based life sciences company supporting academic institutions and pharmaceutical and biotech companies in research of gene functions and drug discovery. Its core product effort is the TrueMAB™ monoclonal antibody collection. The company is building a collection intended to cover the entire human genome of approximately 20,000 genes. OriGene completed a $16m Series B financing to fund that buildout. The round was led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO, with participation from previous investors Morningside Venture Investments and President International Development Corp. (PIDC). The proceeds will enable OriGene to continue expanding the TrueMAB collection.

Total raised

$37M

Funding rounds

3

Latest round

Series C

Latest activity

Mar 2013